6.58

2.97% 0.19

After Hours: 6.70 0.12 +1.82%

Recursion Pharmaceuticals Inc (RXRX)

Overview News Price History Option Chain Financials Why RXRX Down? Discussions Forecast

Recursion Pharmaceuticals Inc stock is traded at $6.58, with a volume of 13.65M. It is up +2.97% in the last 24 hours and down -39.47% over the past month. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Previous Close:

$6.39

Open:

$6.4

24h Volume:

13.65M

Relative Volume:

0.62

Market Cap:

$2.65B

Revenue:

$64.60M

Net Income/Loss:

$-377.75M

P/E Ratio:

-4.2452

EPS:

-1.55

Net Cash Flow:

$-335.64M

1W Performance:

+6.65%

1M Performance:

-39.47%

6M Performance:

-5.19%

1Y Performance:

-38.79%

1-Day Range:

$6.36

$6.75

1-Week Range:

$5.84

$6.89

52-Week Range:

$5.60

$12.36

Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile

Name

Recursion Pharmaceuticals Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

(385) 269-0203

Address

41S RIO GRANDE STREET, SALT LAKE CITY

Employee

800

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

RXRX's Discussions on Twitter

Compare RXRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RXRX Recursion Pharmaceuticals Inc	6.58	2.65B	64.60M	-377.75M	-335.64M	-1.55
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-23	Initiated	Morgan Stanley	Equal-Weight
Mar-16-23	Initiated	Needham	Buy
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-21	Initiated	Berenberg	Buy
May-11-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Goldman	Neutral
May-11-21	Initiated	JP Morgan	Neutral
May-11-21	Initiated	KeyBanc Capital Markets	Overweight
May-11-21	Initiated	SVB Leerink	Outperform

View All

Recursion Pharmaceuticals Inc Stock (RXRX) Latest News

Mar 18, 2025

RXRX Quantitative Stock AnalysisBenjamin Graham - Nasdaq

Mar 18, 2025

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering - Yahoo Finance

Mar 18, 2025

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday? - Yahoo Finance

Mar 18, 2025

Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? - Zacks Investment Research

Mar 18, 2025

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun - Yahoo Finance

Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025

Mar 17, 2025

Recursion Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga

Mar 17, 2025

Mar 14, 2025

Jones Financial Companies Lllp Has $229,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 14, 2025

Mar 13, 2025

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL

Mar 13, 2025

HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer - Business Wire

Mar 13, 2025

Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 13, 2025

Mar 12, 2025

Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha

Mar 12, 2025

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey

Mar 12, 2025

Mar 10, 2025

Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN

Mar 10, 2025

Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga

Mar 08, 2025

QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 08, 2025

Mar 07, 2025

This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga

Mar 07, 2025

Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 07, 2025

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN

Mar 07, 2025

This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail

Mar 07, 2025

Mar 06, 2025

April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq

Mar 06, 2025

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN

Mar 06, 2025

IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 06, 2025

Recursion Pharmaceuticals (RXRX) Remains Optimistic Despite Q4 Disappointment - TipRanks

Mar 06, 2025

TechBio Latest News - substack.com

Mar 06, 2025

Mar 05, 2025

How To Trade (RXRX) - Stock Traders Daily

Mar 05, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN

Mar 05, 2025

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts - Yahoo Finance

Mar 05, 2025

Recursion Pharmaceuticals Shares Dip Amid Revenue Timing - TipRanks

Mar 05, 2025

Mar 04, 2025

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday - MSN

Mar 04, 2025

Rhumbline Advisers Has $2.26 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World

Mar 04, 2025

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% on Disappointing Earnings - Defense World

Mar 04, 2025